Cargando…
Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies
BACKGROUND: Seroprevalence studies of coronavirus disease 2019 (COVID-19) cases, including asymptomatic and past infections, are important to estimate the scale of the disease outbreak and to establish quarantine measures. We evaluated the clinical performance of severe acute respiratory syndrome co...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Laboratory Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368235/ https://www.ncbi.nlm.nih.gov/pubmed/34374351 http://dx.doi.org/10.3343/alm.2022.42.1.71 |
_version_ | 1783739166702436352 |
---|---|
author | Park, Younhee Hong, Ki Ho Lee, Su-Kyung Hyun, Jungwon Oh, Eun-Jee Lee, Jaehyeon Lee, Hyukmin Song, Sang Hoon Kee, Seung-Jung Kwon, Gye Cheol Kim, Su Hwan Do, Hyeon-Nam Kim, Ah-Ra Lee, June-Woo Kim, Sung Soon Kim, Hyun Soo |
author_facet | Park, Younhee Hong, Ki Ho Lee, Su-Kyung Hyun, Jungwon Oh, Eun-Jee Lee, Jaehyeon Lee, Hyukmin Song, Sang Hoon Kee, Seung-Jung Kwon, Gye Cheol Kim, Su Hwan Do, Hyeon-Nam Kim, Ah-Ra Lee, June-Woo Kim, Sung Soon Kim, Hyun Soo |
author_sort | Park, Younhee |
collection | PubMed |
description | BACKGROUND: Seroprevalence studies of coronavirus disease 2019 (COVID-19) cases, including asymptomatic and past infections, are important to estimate the scale of the disease outbreak and to establish quarantine measures. We evaluated the clinical performance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays available in Korea for use in seroprevalence studies. METHODS: The sensitivity, specificity, cross-reactivity, and interference of five SARS-CoV-2 antibody assays were evaluated using the following 398 serum samples from confirmed COVID-19 patients, 510 negative control samples from before 2018 (pre-pandemic), 163 serum samples from patients with SARS, Middle East respiratory syndrome (MERS), and other viral infections, and five samples for the interference study. RESULTS: The sensitivities of the five assays ranged from 92.2% to 98%, and their specificities, including cross-reactivity and interference, ranged from 97.5% to 100%. The agreement rates were excellent (kappa >0.9). Adjustment of the cutoff values could be considered through ROC curve analysis. The positive predictive values of the individual assays varied from 3.5% to 100% at a 0.1% prevalence but were as high as ≥95% when two assays were combined. CONCLUSIONS: The prevalence of COVID-19 in Korea is considered to be exceptionally low at present; thus, we recommend using a combination of two or more SARS-CoV-2 antibody assays rather than a single assay. These results could help select SARS-CoV-2 antibody assays for COVID-19 seroprevalence studies in Korea. |
format | Online Article Text |
id | pubmed-8368235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean Society for Laboratory Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-83682352022-01-01 Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies Park, Younhee Hong, Ki Ho Lee, Su-Kyung Hyun, Jungwon Oh, Eun-Jee Lee, Jaehyeon Lee, Hyukmin Song, Sang Hoon Kee, Seung-Jung Kwon, Gye Cheol Kim, Su Hwan Do, Hyeon-Nam Kim, Ah-Ra Lee, June-Woo Kim, Sung Soon Kim, Hyun Soo Ann Lab Med Original Article BACKGROUND: Seroprevalence studies of coronavirus disease 2019 (COVID-19) cases, including asymptomatic and past infections, are important to estimate the scale of the disease outbreak and to establish quarantine measures. We evaluated the clinical performance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody assays available in Korea for use in seroprevalence studies. METHODS: The sensitivity, specificity, cross-reactivity, and interference of five SARS-CoV-2 antibody assays were evaluated using the following 398 serum samples from confirmed COVID-19 patients, 510 negative control samples from before 2018 (pre-pandemic), 163 serum samples from patients with SARS, Middle East respiratory syndrome (MERS), and other viral infections, and five samples for the interference study. RESULTS: The sensitivities of the five assays ranged from 92.2% to 98%, and their specificities, including cross-reactivity and interference, ranged from 97.5% to 100%. The agreement rates were excellent (kappa >0.9). Adjustment of the cutoff values could be considered through ROC curve analysis. The positive predictive values of the individual assays varied from 3.5% to 100% at a 0.1% prevalence but were as high as ≥95% when two assays were combined. CONCLUSIONS: The prevalence of COVID-19 in Korea is considered to be exceptionally low at present; thus, we recommend using a combination of two or more SARS-CoV-2 antibody assays rather than a single assay. These results could help select SARS-CoV-2 antibody assays for COVID-19 seroprevalence studies in Korea. Korean Society for Laboratory Medicine 2022-01-01 2022-01-01 /pmc/articles/PMC8368235/ /pubmed/34374351 http://dx.doi.org/10.3343/alm.2022.42.1.71 Text en © Korean Society for Laboratory Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Park, Younhee Hong, Ki Ho Lee, Su-Kyung Hyun, Jungwon Oh, Eun-Jee Lee, Jaehyeon Lee, Hyukmin Song, Sang Hoon Kee, Seung-Jung Kwon, Gye Cheol Kim, Su Hwan Do, Hyeon-Nam Kim, Ah-Ra Lee, June-Woo Kim, Sung Soon Kim, Hyun Soo Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies |
title | Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies |
title_full | Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies |
title_fullStr | Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies |
title_full_unstemmed | Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies |
title_short | Performance Comparison of Five SARS-CoV-2 Antibody Assays for Seroprevalence Studies |
title_sort | performance comparison of five sars-cov-2 antibody assays for seroprevalence studies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8368235/ https://www.ncbi.nlm.nih.gov/pubmed/34374351 http://dx.doi.org/10.3343/alm.2022.42.1.71 |
work_keys_str_mv | AT parkyounhee performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT hongkiho performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT leesukyung performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT hyunjungwon performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT oheunjee performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT leejaehyeon performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT leehyukmin performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT songsanghoon performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT keeseungjung performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT kwongyecheol performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT kimsuhwan performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT dohyeonnam performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT kimahra performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT leejunewoo performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT kimsungsoon performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies AT kimhyunsoo performancecomparisonoffivesarscov2antibodyassaysforseroprevalencestudies |